ACSL4 and neoplasm: Our study findings support BQ323636.1 (BQ), a splice variant of NCOR2, as a key orchestrator of such metabolic reprogramming, driving lipid metabolism via ACSL4 to support tumor growth, survival, and resistance in ER-positive breast cancer.